Oncotelic Therapeutics Inc - OTLC STOCK NEWS

Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.

ONCOTELIC THERAPEUTCS INC (OTLC) is a biotechnology company focused on developing innovative therapies for cancer treatment. With a strong emphasis on research and development, the company is committed to bringing novel treatment options to patients in need. Leveraging cutting-edge technologies and strategic partnerships, ONCOTELIC THERAPEUTCS aims to revolutionize cancer care and improve patient outcomes. The company's pipeline includes promising drug candidates targeting various types of cancer, with a focus on precision medicine and personalized treatment approaches. Dedicated to advancing the field of oncology, ONCOTELIC THERAPEUTCS is at the forefront of the fight against cancer.

05/08/2024 08:00 AM

News

ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024

Rhea-AI Summary

Oncotelic Therapeutics, Inc (OTCQB:OTLC) will be presenting at the Biopharma Nexus Conference in San Diego 2024. Dr. Andy Hu, Nanomedicine Manager, will discuss Nanomedicines: Past, Present, Future. Dr. Hu is an expert in nanomedicine and biotherapeutics, aiming to enhance human health through innovative technologies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/29/2024 07:00 AM

News

Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.

Rhea-AI Summary

Oncotelic Therapeutics, Inc. has agreed to sell its necroptosis cancer therapy assets to Mosaic ImmunoEngineering, Inc. The deal includes rights to Oncotelic's clinical-stage necroptosis cancer therapies and AI technologies for identifying immunotherapy combinations. Mosaic will issue $15 million in CPMV shares to Oncotelic, with potential for an additional $15 million in shares. The Mosaic team, experienced in bringing oncology products to market, will lead the development. Both companies will collaborate for a smooth transition of technologies. The agreement is subject to negotiation of definitive agreements and customary conditions.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/25/2024 08:10 AM

News

Linkage of Cancer and Lupus in Gliomas Patients

Rhea-AI Summary

Oncotelic Therapeutics, Inc (OTCQB:OTLC) announces a groundbreaking peer-reviewed publication on the therapeutic targeting of negative prognostic markers in low-grade gliomas. The study reveals the crosstalk between TGF-β and IFN signaling pathways, offering new strategies for treating gliomas and Systemic Lupus Erythematosus (SLE). The research identifies IRF5 as a common target for both diseases, potentially revolutionizing cancer treatment by modulating the immune response. Detailed analysis shows that low mRNA levels of TGFB2 and IFNGR2 result in improved survival for LGG patients, highlighting potential therapeutic targets for high-risk patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/04/2024 08:17 AM

News

Invitation to Participate in STOP-PC Clinical Trial

Rhea-AI Summary

Oncotelic Therapeutics, Inc (OTLC) announces the initiation of the STOP-PC clinical trial for advanced pancreatic cancer. The trial focuses on OT-101, a novel RNA therapeutic targeting TGF-β2 to enhance immune response and inhibit tumor growth. Notably, OT-101 has shown promising single-agent activity with dose-dependent survival benefits. The Phase 2/3 trial will evaluate OT-101 in combination with mFOLFIRINOX compared to mFOLFIRINOX alone as second-line therapy for progressing cancer.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

01/16/2024 08:00 AM

News

Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients

Rhea-AI Summary

Oncotelic Therapeutics, Inc announced the publication of a study on the impact of TGFB2 and IFNGR2 mRNA levels in pediatric DMG patients. The study reveals that elevated TGFB2 levels worsen mortality in DMG patients and highlights the potential of IFNGR2 in enhancing immune surveillance for cancer immunotherapy. The findings suggest that targeting TGFB2 and IFNGR2 could lead to improved overall survival outcomes for pbDMG patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/18/2023 08:10 AM

News

Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant

Rhea-AI Summary

Oncotelic Therapeutics, Inc (OTCQB:OTLC) unveils a state-of-the-art GMP Manufacturing Plant in a joint venture with Sapu Biosciences LLC, marking a significant stride in biopharmaceutical innovation and a pivotal expansion in the company's clinical pipeline.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/28/2023 07:10 AM

News

Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit.

Rhea-AI Summary

Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced its CEO, Dr. Vuong Trieu, will be a featured speaker at the Ibero-American Chatbot and Conversational AI Summit. He will discuss the Company’s proprietary chatbots, part of the Orion AI Technology suite, at the November 29th and 30th, 2023 summit. The chatbots aim to overcome traditional AI communication challenges and have multilingual capabilities, advancing global participation in biotechnological innovation.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/15/2023 09:00 AM

News

Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results

Rhea-AI Summary

Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced financial results for Q3 2023, showing unchanged R&D costs, significantly lower G&A costs, and reduced net loss and operating expenses. The company is benefitting from a joint venture with Dragon Overseas Limited, which has absorbed most R&D and G&A expenditures related to OT-101, allowing the company to continue development efforts at no cash cost. Plans for an initial public offering of the joint venture in Hong Kong or another exchange are in progress, and the company aims to accelerate clinical programs in multiple indications.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/25/2023 07:00 AM

News

Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023

Rhea-AI Summary

Oncotelic Therapeutics featured in Life Sciences Review and awarded Top Cancer Immunotherapy Solutions Provider 2023

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-33.33%

Tags

08/23/2023 07:10 AM

News

Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer

Rhea-AI Summary

Oncotelic announces joint venture for registrational trial in pancreatic cancer

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

50%

Tags

FAQ

What is the current stock price of Oncotelic Therapeutics (OTLC)?

The current stock price of Oncotelic Therapeutics (OTLC) is $0.0395 as of February 28, 2025.

What is the market cap of Oncotelic Therapeutics (OTLC)?

The market cap of Oncotelic Therapeutics (OTLC) is approximately 10.2M.

What is ONCOTELIC THERAPEUTCS INC (OTLC) focused on?

ONCOTELIC THERAPEUTCS is a biotechnology company specializing in developing innovative cancer therapies.

What sets ONCOTELIC THERAPEUTCS apart from other biotech companies?

ONCOTELIC THERAPEUTCS stands out for its strong focus on research and development, cutting-edge technologies, and strategic partnerships.

What does the pipeline of ONCOTELIC THERAPEUTCS include?

The company's pipeline features promising drug candidates targeting various types of cancer, with an emphasis on precision medicine and personalized treatment.

How does ONCOTELIC THERAPEUTCS contribute to the field of oncology?

ONCOTELIC THERAPEUTCS is dedicated to advancing oncology by bringing novel treatment options to patients and improving outcomes.

What is the mission of ONCOTELIC THERAPEUTCS?

The mission of ONCOTELIC THERAPEUTCS is to revolutionize cancer care through innovation, research, and strategic collaborations.

Is ONCOTELIC THERAPEUTCS committed to patient-centric care?

Yes, ONCOTELIC THERAPEUTCS is committed to patient-centric care by focusing on precision medicine and personalized treatment approaches.

What are some recent achievements of ONCOTELIC THERAPEUTCS?

ONCOTELIC THERAPEUTCS has achieved significant milestones in drug development and research, positioning itself as a leader in the oncology space.

How does ONCOTELIC THERAPEUTCS leverage cutting-edge technologies?

ONCOTELIC THERAPEUTCS utilizes cutting-edge technologies to drive innovation in cancer therapy and improve patient outcomes.

What partnerships does ONCOTELIC THERAPEUTCS have in the industry?

ONCOTELIC THERAPEUTCS has strategic partnerships with key stakeholders in the biopharmaceutical industry to further its research and development efforts.

How does ONCOTELIC THERAPEUTCS aim to revolutionize cancer care?

ONCOTELIC THERAPEUTCS aims to revolutionize cancer care by bringing novel therapies to market, advancing precision medicine, and enhancing patient outcomes.